Related Experiment Videos
[Cryofibrinogenemia--successful therapy by decreasing fibrinogen]
1Hautklinik der Christian-Albrechts-Universität Kiel.
Summary
This study shows batroxobin/ancrod injections effectively treat cryofibrinogenaemia, significantly reducing symptoms like cold-induced pain. Careful monitoring of fibrinogen levels ensures this therapy is safe and efficient for patients.
Area of Science:
- Hematology
- Pharmacology
- Toxicology
Background:
- Cryofibrinogenaemia is a rare condition characterized by the presence of cryofibrinogens in the blood.
- It can be idiopathic or secondary to various conditions, including infections and chronic diseases.
- Symptoms often include pain, particularly after cold exposure, and potential complications like thrombosis.
Observation:
- Six patients with solitary cryofibrinogenaemia were treated with subcutaneous injections of batroxobin/ancrod.
- These patients had either idiopathic or secondary cryofibrinogenaemia linked to diverse underlying conditions.
- Treatment duration varied, with several weeks of administration.
Findings:
- Five out of six patients achieved near-complete symptom remission, notably pain relief upon cold exposure.
- One patient experienced partial symptom relief.
- An overall 75% reduction in symptoms was observed across the patient group.
- Blood fibrinogen levels were closely monitored throughout the treatment.
Implications:
- Subcutaneous batroxobin/ancrod injections represent an efficient and safe therapeutic option for cryofibrinogenaemia.
- This treatment can significantly improve the quality of life for patients suffering from this condition.
- Careful monitoring of fibrinogen levels is crucial for safe and effective application of this therapy.